Prof. Dan Peer

Prof. Dan Peer is the Director of the Laboratory of Precision NanoMedicine at Tel Aviv University (TAU). He is currently the Vice President for Research & Development at Tel Aviv University. From 2016-2020, he was the Chair of Tel Aviv University Cancer Biology Research Center; the biggest Cancer Center in Israel that includes 17 affiliated hospitals and from 2017 he is the Founding and Managing Director of SPARK Tel Aviv, Center for Translational Medicine at TAU.


Prof. Peer’s work was among the first to demonstrate systemic delivery of RNA molecules using targeted nanocarriers to the immune system and he pioneered the use of RNA interference (RNAi) as drug discovery tools in immune cells. In addition, his lab was the first to show systemic, cell specific delivery of modified mRNA to cells to induce therapeutic gene expression of desired proteins within the immune system that has enormous applications in cancer, inflammation and infection diseases (e.g. Vaccines against COVID19). Recently, his lab showed the first, systemic cell specific, high efficiency therapeutic genome editing in cancer that can become a novel therapeutic modality.


​Prof. Peer and his team have done innovative and groundbreaking work in cancer, mostly in brain tumors (Glioblastoma), Ovarian Cancer, and a set of blood cancers (Mantle Cell Lymphoma, Multiple Myeloma and Chronic Lymphocytic Leukemia). 
In his work in Mantle Cell Lymphoma and Multiple Myeloma is now being translated into clinical trials.


His work is published in premier scientific journals and he is the editor and author of several books in the field of nanomedicine. In addition, he is an associate editor of Journal of Controlled Release, and a member of the editorial boards of numerous journals including Cancer Letters and ACS Bioconjugate Chemistry.  He has received more than 30 awards; among them, he was recognized by the Kenneth Rainin Foundation by their Innovator (2010) and Breakthrough (2011 – 2013) Awards for his pioneering work in inflammatory bowel diseases and by the AAAS and the Untold news breakthrough Award for his development of the Gagomers platform for cancer targeted drug delivery. In 2017, he received the 2017 Nanos Award for major contribution to the field of clinical nanomedicine in CLINAM 10th, Basal, Switzerland.


Prof. Peer has more than 120 pending and granted patents. Some of them have been licensed to several pharmaceutical companies and one is currently under registration. In addition, based on his work, five spin-off companies were generated aiming to bring innovative personalized molecular medicines into clinical practice using nanotechnology. 


Contact info:

Prof. Dan Peer, PhD (full biography)

Cell research and Immunology Department,

The Shmunis School of Biomedicine and Cancer Research

The George S. Wise Faculty of Life Sciences


Tel Aviv University makes every effort to respect copyright. If you own copyright to the content contained
here and / or the use of such content is in your opinion infringing, Contact us as soon as possible >>